Korean Circ J.  2023 Feb;53(2):69-91. 10.4070/kcj.2022.0255.

Advancing Cardio-Oncology in Asia

• Ng CT
• Tan LL
• Sohn IS
• Bonilla HG
• Oka T
• Yinchoncharoen T
• Chang WT
• Chong JH
• Tan MKC
• Cruz RR
• Astuti A
• Agarwala V
• Chien V
• Youn JC
• Tong J
• Herrmann J

• KMID: 2539485
• DOI: http://doi.org/10.4070/kcj.2022.0255

Abstract

Cardio-oncology is an emerging multi-disciplinary field, which aims to reduce morbidity and mortality of cancer patients by preventing and managing cancer treatment-related cardiovascular toxicities. With the exponential growth in cancer and cardiovascular diseases in Asia, there is an emerging need for cardio-oncology awareness among physicians and country-specific cardio-oncology initiatives. In this state-of-the-art review, we sought to describe the burden of cancer and cardiovascular disease in Asia, a region with rich cultural and socio-economic diversity. From describing the uniqueness and challenges (such as socio-economic disparity, ethnical and racial diversity, and limited training opportunities) in establishing cardio-oncology in Asia, and outlining ways to overcome any barriers, this article aims to help advance the field of cardio-oncology in Asia.

Keyword

Cardio-oncology; Onco-cardiology; Cardiotoxicity; Asia; Cancer

Figure

• 

  Figure 1 Deaths by cause, South-East Asia region (WHO), 1990??019, showing a shift in mortality from communicable, maternal, neonatal and nutritional disease to non-communicable diseases in South-East Asia.4)NCD = non-communicable disease; WHO = World Health Organization.

• 

  Figure 2 Burden of disease by cause, world, 2019. Total disease burden, measured in DALYs by sub-category of disease or injury. DALYs measure the total burden of disease—both from years of life lost due to premature death and years lived with a disability. One DALY equals one lost year of healthy life.4) DALY = disability-adjusted life year; HIV/AIDS = human immunodeficiency virus/acquired immunodeficiency syndrome; NCD = non-communicable disease; STI = sexually transmitted infection; TB = tuberculosis.

• 

  Figure 3 Top cancer per country, estimated age-standardized incidence rates in 2020, both sexes, all ages, excluding NMSC.19) NMSC = non-melanoma skin cancer.Data source: GLOBOCAN 2020; Map production: International Agency for Research on Cancer, World Health Organization.

• 

  Figure 4 Survival outcomes from time of cancer diagnosis stratified by pre-existing and/or newly-diagnosed cardiovascular disease in South Korea.24)

• 

  Figure 5 (A) Data on from 2015 ESMO International Consortium Study on the availability, out-of-pocket costs and accessibility of antineoplastic medicines in countries outside of Europe: Asian data for medications on the WHO Model List of Essential Medicines: formulary availability and out-of-pocket costs. (B) Data from the 2015 ESMO International Consortium Study on the availability, out-of-pocket costs and accessibility of antineoplastic medicines in countries outside of Europe: Asian data of recently approved medications not on the WHO Model List of Essential Medicines, with an ESMO-MCBS score greater than 2: formulary availability and out-of-pocket costs.33)Abirat = abiraterone; Aftatin = atafinib; Anast = anastrozole; Axitin = axitinib; Bleo = bleomycin; Capecit = capecitabine; CarboP = carboplatin; Cetux = cetuximab; CisP = cisplatin; Crizot = crizotinib; CRC = colorectal cancer; Cyclo = cyclophosphamide; DTIC = dacarbazine; Docet = docetaxel; Enzalut = enzalutamide; Epir = eprirubicin; Erlot = erlotinib; ESMO = European Society for Medical Oncology; Etop = etoposide; Everol = everolimus; Gefit = gefitinib; Ifos = ifosfamide; Ipilim = ipilimumab; Irino = irinotecan; Lapat = lapatinib; MBC = metastatic breast cancer; MCBS = Magnitude of Clinical Benefit Scale; Melan = melanoma; MTX = methotrexate; Oxalipl = oxaliplatin; Paclit = paclitaxel; Panitum = panitumumab; Pazop = pazopanib; Pertuz = pertuzumab; Prost = prostate; RCC = renal cell cancer; Soraf = sorafenib; Suni = sunitinib; Tam = tamoxifen; Temsir = temsirolimus; Trastuz = trastuzumab; VBL = vinblastine; VCR = vincristine; Vemuraf = vemurafenib; WHO = World Health Organization.

• 

  Figure 6 Outcomes of a cardio-oncology in Taiwan.49)HF = heart failure; HTN = hypertension; MI = myocardial infarction.

• 

  Figure 7 Worldwide distribution of International Cardio-Oncology Society Centers of cardio-oncology excellence.51) ICOS = International Cardio-Oncology Society.

• 

  Figure 8 Central elements of cardio-oncology training.2)

• 

  Figure 9 Intradisciplinary and cross-specialty collaboration among cardiologists, hematologist and oncologists in cardio-oncology.2)

• 

  Figure 10 Key components of a cardio-oncology program.65)ACC = American College of Cardiology; ASCO = American Society of Clinical Oncology; CV = cardiovascular.

Reference

1. Falzone L, Salomone S, Libra M. Evolution of cancer pharmacological treatments at the turn of the third millennium. Front Pharmacol. 2018; 9:1300. PMID: 30483135.

2. Alvarez-Cardona JA, Ray J, Carver J, et al. Cardio-oncology education and training: JACC Council perspectives. J Am Coll Cardiol. 2020; 76:2267–2281. PMID: 33153587.

3. Shi S, Lv J, Chai R, et al. Opportunities and challenges in cardio-oncology: a bibliometric analysis from 2010 to 2022. Curr Probl Cardiol. 2022; 101227. PMID: 35500730.

4. Ritchie H, Spooner F, Roser M. Causes of death [Internet]. place unknown: Our World in Data;2018. cited 2022 August 5. Available from: https://ourworldindata.org/causes-of-death.

5. Zhao D. Epidemiological features of cardiovascular disease in Asia. JACC Asia. 2021; 1:1–13. PMID: 36338365.

6. Global Burden of Disease 2019 Cancer Collaboration. Kocarnik JM, Compton K, et al. Cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life years for 29 cancer groups from 2010 to 2019: a systematic analysis for the global burden of disease study 2019. JAMA Oncol. 2022; 8:420–444. PMID: 34967848.

7. Centers for Disease Control and Prevention, National Center for Health Statistics. About multiple cause of death, 1999–2020. CDC WONDER Online Database website [Internet]. Atlanta (GA): Centers for Disease Control and Prevention;2022. cited 2022 February 21. Available from: https://wonder.cdc.gov/.

8. Ng CJ, Teo CH, Abdullah N, Tan WP, Tan HM. Relationships between cancer pattern, country income and geographical region in Asia. BMC Cancer. 2015; 15:613. PMID: 26335225.

9. World Health Organization. Global health estimates: life expectancy and leading causes of death and disability [Internet]. Geneva: World Health Organization;2022. cited 2022 February 8. Available from: https://www.who.int/data/gho/data/themes/mortality-and-global-health-estimates.

10. Cao M, Li H, Sun D, Chen W. Cancer burden of major cancers in China: a need for sustainable actions. Cancer Commun (Lond). 2020; 40:205–210. PMID: 32359212.

11. Liu Y, Zhang YL, Liu JW, Fang FQ, Li JM, Xia YL. Emergence, development, and future of cardio-oncology in China. Chin Med J (Engl). 2018; 131:2640–2644. PMID: 30381608.

12. Oka T, Akazawa H, Sase K, Hatake K, Komuro I. Cardio-oncology in Japan. JACC CardioOncol. 2020; 2:815–818. PMID: 34396300.

13. Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021; 71:209–249. PMID: 33538338.

14. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA Cancer J Clin. 2022; 72:7–33. PMID: 35020204.

15. National Cancer Institute. Surveillance, Epidemiology, and End Results Program. Cancer Stat Facts [Internet]. Bethesda (MD): National Cancer Institute;2022. cited 2022 July 21. Available from: https://seer.cancer.gov.

16. American Cancer Society. The Cancer Atlas [Internet]. Atlanta (GA): American Cancer Society;2022. cited 2022 July 11. Available from: https://canceratlas.cancer.org.

17. Institute for Health Metrics and Evaluation (IHME). Website of IHME [Internet]. Seattle (WA): Institute for Health Metrics and Evaluation;2022. cited 2022 July 7. Available from: https://www.healthdata.org.

18. Centers for Disease Control and Prevention, National Center for Health Statistics. Leading causes of death [Internet]. Atlanta (GA): Centers for Disease Control and Prevention;2022. cited 2022 July 29. Available from: https://www.cdc.gov/nchs/fastats/leading-causes-of-death.htm.

19. Ferlay J, Ervik M, Lam F, Colombet M, Mery L, Piñeros M, Znaor A, Soerjomataram I, Bray F. Global Cancer Observatory: Cancer Today [Internet]. Lyon: International Agency for Research on Cancer;2020. cited 2022 August 10. Available from: https://gco.iarc.fr/today.

20. Kimura T. East meets West: ethnic differences in prostate cancer epidemiology between East Asians and Caucasians. Chin J Cancer. 2012; 31:421–429. PMID: 22085526.

21. Gilchrist SC, Barac A, Ades PA, et al. Cardio-oncology rehabilitation to manage cardiovascular outcomes in cancer patients and survivors: a scientific statement from the American Heart Association. Circulation. 2019; 139:e997–1012. PMID: 30955352.

22. Kwan ML, Cheng RK, Iribarren C, et al. Risk of heart failure with preserved versus reduced ejection fraction in women with breast cancer. Breast Cancer Res Treat. 2022; 193:669–675. PMID: 35429322.

23. Paterson DI, Wiebe N, Cheung WY, et al. Incident cardiovascular disease among adults with cancer: a population-based cohort study. JACC CardioOncol. 2022; 4:85–94. PMID: 35492824.

24. Youn JC, Chung WB, Ezekowitz JA, et al. Cardiovascular disease burden in adult patients with cancer: an 11-year nationwide population-based cohort study. Int J Cardiol. 2020; 317:167–173. PMID: 32360647.

25. Strongman H, Gadd S, Matthews AA, et al. Does cardiovascular mortality overtake cancer mortality during cancer survivorship?: an English retrospective cohort study. JACC CardioOncol. 2022; 4:113–123. PMID: 35492818.

26. Agarwala V, Choudhary N, Gupta S. A risk-benefit assessment approach to selection of adjuvant chemotherapy in elderly patients with early breast cancer: a mini review. Indian J Med Paediatr Oncol. 2017; 38:526–534. PMID: 29333024.

27. Okura Y, Takayama T, Ozaki K, et al. Future projection of cancer patients with cardiovascular disease in Japan by the year 2039: a pilot study. Int J Clin Oncol. 2019; 24:983–994. PMID: 30903421.

28. Chongsuvivatwong V, Phua KH, Yap MT, et al. Health and health-care systems in southeast Asia: diversity and transitions. Lancet. 2011; 377:429–437. PMID: 21269685.

29. The World Bank. World Bank open data [Internet]. Washington, D.C.: The World Bank;2022. cited 2022 July 29. Available from: https://data.worldbank.org/.

30. Rahman MM, Karan A, Rahman MS, et al. Progress toward universal health coverage: a comparative analysis in 5 South Asian countries. JAMA Intern Med. 2017; 177:1297–1305. PMID: 28759681.

31. Ohman RE, Yang EH, Abel ML. Inequity in cardio-oncology: identifying disparities in cardiotoxicity and links to cardiac and cancer outcomes. J Am Heart Assoc. 2021; 10:e023852. PMID: 34913366.

32. Economic and Social Commission for Asia and the Pacific. Inequality in Asia and the Pacific [Internet]. Bangkok: Economic and Social Commission for Asia and the Pacific;2022. cited 2022 July 11. https://www.unescap.org/sites/default/d8files/01ExecutiveSummary.pdf .

33. Eniu A, Cherny NI, Bertram M, et al. Cancer medicines in Asia and Asia-Pacific: what is available, and is it effective enough? ESMO Open. 2019; 4:e000483. PMID: 31423334.

34. Goh BC, Lim JF. Cancer drugs in Asian populations: availability, accessibility, and affordability. Cancer J. 2020; 26:323–329. PMID: 32732675.

35. Leighl NB, Nirmalakumar S, Ezeife DA, Gyawali B. An arm and a leg: the rising cost of cancer drugs and impact on access. Am Soc Clin Oncol Educ Book. 2021; 41:1–12.

36. IQVIA Institute. Global Oncology Trends 2022. Durham (NC): IQVIA Institute;2022.

37. Kimman M, Jan S, Yip CH, et al. ACTION Study Group. Catastrophic health expenditure and 12-month mortality associated with cancer in Southeast Asia: results from a longitudinal study in eight countries. BMC Med. 2015; 13:190. PMID: 26282128.

38. Venkatakrishnan K, Burgess C, Gupta N, et al. Toward optimum benefit-risk and reduced access lag for cancer drugs in Asia: a global development framework guided by clinical pharmacology principles. Clin Transl Sci. 2016; 9:9–22. PMID: 26836226.

39. Frankart AJ, Nagarajan R, Pater L. The impact of proton therapy on cardiotoxicity following radiation treatment. J Thromb Thrombolysis. 2021; 51:877–883. PMID: 33033980.

40. Gupta M, Singh N, Verma S. South Asians and cardiovascular risk: what clinicians should know. Circulation. 2006; 113:e924–e929. PMID: 16801466.

41. Kario K, Chen CH, Park S, et al. Consensus document on improving hypertension management in Asian patients, taking into account Asian characteristics. Hypertension. 2018; 71:375–382. PMID: 29311253.

42. Telli ML, Chang ET, Kurian AW, et al. Asian ethnicity and breast cancer subtypes: a study from the California Cancer Registry. Breast Cancer Res Treat. 2011; 127:471–478. PMID: 20957431.

43. Zhou W, Christiani DC. East meets West: ethnic differences in epidemiology and clinical behaviors of lung cancer between East Asians and Caucasians. Chin J Cancer. 2011; 30:287–292. PMID: 21527061.

44. O’Donnell PH, Dolan ME. Cancer pharmacoethnicity: ethnic differences in susceptibility to the effects of chemotherapy. Clin Cancer Res. 2009; 15:4806–4814. PMID: 19622575.

45. Hao W, Shi YY, Qin YN, et al. Cardioprotective effect of Chinese herbal medicine for anthracycline-induced cardiotoxicity in cancer patients: a meta-analysis of prospective studies. Medicine (Baltimore). 2022; 101:e29691. PMID: 35905252.

46. Cheng RK. Developing a cardio-oncology program from an early career perspective: challenges faced and lessons learned [Internet]. Washington, D.C.: American College of Cardiology;2018. cited 2022 September 1. Available from: https://www.acc.org/membership/sections-and-councils/imaging-section/section-updates/2018/01/03/22/05/developing-a-cardio-oncology-program-from-an-early-career-perspective-challenges-faced-and-lessons-learned.

47. Bhatia N, Lenihan D, Sawyer DB, Lenneman CG. Getting the SCOOP-survey of cardiovascular outcomes from oncology patients during survivorship. Am J Med Sci. 2016; 351:570–575. PMID: 27238918.

48. Herrmann J, Loprinzi C, Ruddy K. Building a cardio-onco-hematology program. Curr Oncol Rep. 2018; 20:81. PMID: 30203261.

49. Chang WT, Feng YH, Kuo YH, et al. The impact of a multidisciplinary cardio-oncology programme on cardiovascular outcomes in Taiwan. ESC Heart Fail. 2020; 7:2135–2139. PMID: 32621792.

50. Pareek N, Cevallos J, Moliner P, et al. Activity and outcomes of a cardio-oncology service in the United Kingdom-a five-year experience. Eur J Heart Fail. 2018; 20:1721–1731. PMID: 30191649.

51. International Cardio-Oncology Society. IC-OS Centers of excellence certification [Internet]. Tampa (FL): International Cardio-Oncology Society;2022. cited 2022 August 20. Available from: https://ic-os.org/excellence-certification/.

52. Lyon AR, Dent S, Stanway S, et al. Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: a position statement and new risk assessment tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in collaboration with the International Cardio-Oncology Society. Eur J Heart Fail. 2020; 22:1945–1960. PMID: 32463967.

53. Hayek SS, Ganatra S, Lenneman C, et al. Preparing the cardiovascular workforce to care for oncology patients: JACC review topic of the week. J Am Coll Cardiol. 2019; 73:2226–2235. PMID: 31047011.

54. Peng J, Rushton M, Johnson C, et al. An international survey of healthcare providers’ knowledge of cardiac complications of cancer treatments. Cardiooncology. 2019; 5:12. PMID: 32154018.

55. Xia Y, Liu J. Working together to advance cardio-oncology in China. JACC CardioOncol. 2020; 2:144–145. PMID: 34396222.

56. Kim H, Chung WB, Cho KI, et al. Diagnosis, treatment, and prevention of cardiovascular toxicity related to anti-cancer treatment in clinical practice: an opinion paper from the Working Group on Cardio-Oncology of the Korean Society of Echocardiography. J Cardiovasc Ultrasound. 2018; 26:1–25. PMID: 29629020.

57. Bhatt DL. Birth and maturation of cardio-oncology. JACC CardioOncol. 2019; 1:114–116. PMID: 34396168.

58. Yoon GJ, Telli ML, Kao DP, Matsuda KY, Carlson RW, Witteles RM. Left ventricular dysfunction in patients receiving cardiotoxic cancer therapies are clinicians responding optimally? J Am Coll Cardiol. 2010; 56:1644–1650. PMID: 21050974.

59. Oren O, Neilan TG, Fradley MG, Bhatt DL. Cardiovascular safety assessment in cancer drug development. J Am Heart Assoc. 2021; 10:e024033. PMID: 34913360.

60. McCain K, Hardesty C, Wong A. Charting a course to remodel universal healthcare in the Asia-Pacific [Internet]. Cologny: World Economic Forum;2021. cited 2022 July 16. Available from: https://www.weforum.org/agenda/2021/11/how-to-remodel-universal-healthcare-in-the-asia-pacific/.

61. Khalid A. Expanding universal health coverage in Asia [Internet]. Tacoma (WA): The Borgen Project;2015. cited 2022 August 25. Available from: https://borgenproject.org/universal-health-care-in-asia/.

62. Lagomarsino G, Garabrant A, Adyas A, Muga R, Otoo N. Moving towards universal health coverage: health insurance reforms in nine developing countries in Africa and Asia. Lancet. 2012; 380:933–943. PMID: 22959390.

63. Addison D, Campbell CM, Guha A, Ghosh AK, Dent SF, Jneid H. Cardio-oncology in the era of the COVID-19 pandemic and beyond. J Am Heart Assoc. 2020; 9:e017787. PMID: 32713239.

64. Evans WK, Ashbury FD, Hogue GL, Smith A, Pun J. Implementing a regional oncology information system: approach and lessons learned. Curr Oncol. 2014; 21:224–233. PMID: 25302031.

65. Sadler D, Chaulagain C, Alvarado B, et al. Practical and cost-effective model to build and sustain a cardio-oncology program. Cardiooncology. 2020; 6:9. PMID: 32690995.

66. Herrmann J, Lenihan D, Armenian S, et al. Defining cardiovascular toxicities of cancer therapies: an International Cardio-Oncology Society (IC-OS) consensus statement. Eur Heart J. 2022; 43:280–299. PMID: 34904661.

67. Jahangir E. The need for precision cardio-oncology [Internet]. Washington, D.C.: American College of Cardiology;2020. cited 2022 August 2. Available from: https://www.acc.org/latest-in-cardiology/articles/2020/09/21/19/13/the-need-for-precision-cardio-oncology.

68. Rhee JW, Ky B, Armenian SH, Yancy CW, Wu JC. Primer on biomarker discovery in cardio-oncology: application of omics technologies. JACC CardioOncol. 2020; 2:379–384. PMID: 33073248.

69. Gerik L. Cardio-oncology, then and now: an interview with Barry Trachtenberg. Methodist DeBakey Cardiovasc J. 2019; 15:e1–e3.

70. Dreyfuss AD, Bravo PE, Koumenis C, Ky B. Precision cardio-oncology. J Nucl Med. 2019; 60:443–450. PMID: 30655328.

71. Attia ZI, Kapa S, Lopez-Jimenez F, et al. Screening for cardiac contractile dysfunction using an artificial intelligence-enabled electrocardiogram. Nat Med. 2019; 25:70–74. PMID: 30617318.

72. Zhou Y, Hou Y, Hussain M, et al. Machine learning-based risk assessment for cancer therapy-related cardiac dysfunction in 4300 longitudinal oncology patients. J Am Heart Assoc. 2020; 9:e019628. PMID: 33241727.

73. Chaix MA, Parmar N, Kinnear C, et al. Machine learning identifies clinical and genetic factors associated with anthracycline cardiotoxicity in pediatric cancer survivors. JACC CardioOncol. 2020; 2:690–706. PMID: 34396283.

74. Sadler DB, Moudgil R, Arco T, et al. Abstract 11675: Global cardio oncology registry: structure for a multinational collaboration. Circulation. 2021; 144(Suppl 1):11675.